

## PROXY: GENOMMA LAB INFORMS THE AMOUNT TO BE PROPOSED TO THE SHAREHOLDER'S MEETING FOR THE CANCELLATION OF BUYBACK SHARES

**Mexico City, April 12, 2024— Genomma Lab Internacional, S.A.B. de C.V. (BMV: LABB)** (“Genomma Lab” or “the Company”), one of the leading pharmaceutical and personal care products companies in Mexico with an increasing international presence, informs that the maximum amount to be proposed, to the Annual General Shareholders Meeting, for the cancellation of buyback shares that are currently held by the Company, is up to 20 million.

Additionally, approval from the Annual General Shareholders Meeting will be requested to cancel up to 100 million additional buyback shares currently, or in the future, held by the Company and to delegate authorities to the Board of Directors to determine the definitive amount, dates and other terms and conditions of any such additional buyback share cancellations, within the maximum amount of shares to be canceled authorized by the Shareholders Meeting.

Please note that shares that will be proposed for cancellation are buyback shares acquired or to be acquired in transactions made in terms of Article 56 of Mexican Securities Market Law.

The cancellation of buyback shares (as such shares are owned by the Company) (i) will not give rise to any capital, stock or any other similar redemption payments and (ii) is not expected to result in differences regarding shareholders rights.

### **About Genomma Lab Internacional**

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of Premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low-cost, highly flexible supply chain operating model. For more information visit: [www.genommalab.com](http://www.genommalab.com)  
Genomma Lab's shares are listed on the Mexican Stock Exchange under the ticker “**LABB**” (**Bloomberg: LABB:MM**).

### **Note on Forward-Looking Statements**

This report may contain certain forward-looking statements and information relating to the Company that reflect the current views and/or expectations of the Company and its management with respect to its performance, business and future events. Forward looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain words like “believe,” “anticipate,” “expect,” “envisages,” “will likely result,” or any other words or phrases of similar meaning. Such statements are subject to a number of risks, uncertainties and assumptions. We caution you that a number of important factors could cause actual results to differ materially from the plans, objectives, expectations, estimates and intentions expressed in this presentation and in oral statements made by authorized officers of the Company. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of their dates. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.